From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Fungi (Basel) 4, 50
Enforcement is currently a game of Whack-A-Mole
Together they target the root cause of pigmentation-driven dark circles, not just puffiness
And this is possible through a mechanism working with collagen synthesis
Replication of epidemiological associations of carpal tunnel syndrome in a UK population-based cohort of over 400,000 people
